摘要
目的评价羟基脲治疗类白血病反应的用药合理性,为临床应用提供参考依据。方法结合1例男性肺腺癌Ⅳ期合并类白血病反应患者应用羟基脲降低白细胞,同时联合培美曲塞+卡铂化疗的治疗方案,从羟基脲药物剂量、用药疗程及化疗方案的选择等方面分析其用药合理性。结果经治疗后患者症状有缓解但随后出现Ⅳ度骨髓抑制,经药物及输血治疗后未见好转,其治疗过程中羟基脲的用量偏高,采用含卡铂两药联合方案,进一步加重了患者的骨髓抑制。结论羟基脲具有降低白细胞的作用,但是在治疗实体瘤合并类白血病反应中的用法以及与化疗方案的联合方式都需要进一步的探索和更多临床数据的支持。
Objective To determine the rationality of hydroxyurea for leukemoid so as to provide reference for the reasonable application of hydroxyurea. Methods One male patient with lung adenocarcinoma combined with stage IV leukemoid reaction with was treated with hydroxyurea. The white blood cell was reduced and pemetrexed plus carboplatin regimen chemotherapy was used. We analyzed the rationality of drug use from hydroxyurea dosage, course of treatment and the choice of chemotherapy. Results The symptoms were relieved after treatment, but there was IV grade myelosuppression, and no improvement was found after the treatment with drugs and blood transfusion. The high amount of hydroxyurea and the combination of chemotherapy with carboplatin further increased the bone marrow suppression in the patient. Conclusion Despite decreasing the white blood cells, hydroxyurea in the treatment of solid tumors with leukemoid reaction needs further exploration and more clinical support.
出处
《中南药学》
CAS
2017年第4期521-523,共3页
Central South Pharmacy
关键词
羟基脲
肺腺癌
类白血病反应
合理性评价
hydroxyurea
lung adenocarcinoma
leukemoid reaction
rationality
